Page 49 - Linical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital – featuring Dr. Anthony Fauci, Director of NIAID at the NIH – will focus on four decades of innovation as well as the critical importance of collaboration and investment moving forward. On June 5, 1981, the Centers for Disease Control’s Morbidity and Mortality Weekly Report described 5 cases of  The UN wants to end the AIDS epidemic by 2030. But a key set of global 2020 targets to tackle HIV/AIDS were ‘missed by a long way’:​...

BMS drug Opdivo lands FDA approval for gastro cancers By Jenni Spinner The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy. Bristol Myers Squibb (BMS) announced the US Food and Drug Administration (FDAP has approved Opdivo (nivolumab, injection for intravenous use) for adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have recei...

Despite COVID-19, pharma R&D funding at all-time high: IQVIA According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels. The IQVIA Institute for Human Data Science has released its latest industry latest report, Global Trends in R&D: Overview Through 2020. According to the findings, research and development funding maintained historically high levels, thanks to new funding sources, strategic transactions, and other activity. Murray Aitken, executive director of the IQVIA Inst...

The trial services firm has entered an acquisition agreement with Thoma Bravo, a private equity company centered on software and technology services. Greenphire, a technology firm that provides financial lifecycle management solutions for clinical trials, has entered an agreement with Thoma Bravo, a private equity outfit that focuses on software and technology buys. The deal is expected to wrap in the second quarter of 2021, pending regulatory approvals; financial details were not disclosed. Greenphire CEO Jim Murphy discussed the deal with Outsourcing-Pharma, the ...

The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization. Novartis and Molecular Partners have announced the start of their EMPATHY Phase II/III study to explore the use of its DARPin (designed ankyrin repeat proteins) therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis reportedly will run the trial program, with Molecular Partners serving as sponsor. The EMPATHY clinical trial program is intended to investigate the safety and efficacy of en...